International Journal of Molecular Medical Science, 2025, Vol.15, No.6, 253-262 http://medscipublisher.com/index.php/ijmms 260 Alfaris N., Waldrop S., Johnson V., Boaventura B., Kendrick K., and Stanford F., 2024, GLP-1 single dual and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review, eClinicalMedicine, 75: 102782. https://doi.org/10.1016/j.eclinm.2024.102782 Anderson J., 2020, Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes, Diabetes Spectrum, 33: 165-174. https://doi.org/10.2337/ds19-0031 Aronne L., Hall K., Jakicic J., Leibel R., Lowe M., Rosenbaum M., and Klein S., 2021, Describing the weight‐reduced state: physiology behavior and interventions, Obesity, 29: S9-24. https://doi.org/10.1002/oby.23086 Bednarz K., Kowalczyk K., Cwynar M., Czapla D., Czarkowski W., Kmita D., Nowak A., and Madej P., 2022, The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome, International Journal of Molecular Sciences, 23(8): 4334. https://doi.org/10.3390/ijms23084334 Berg S., Stickle H., Rose S., and Nemec E., 2025, Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: a systematic review and meta‐analysis, Obesity Reviews, 26: e13929. https://doi.org/10.1111/obr.13929 Budini B., Luo S., Tam M., Stead I., Lee A., Akrami A., Vidal-Puig A., and Park A., 2025, Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression, medRxiv, 9: 2025-06. https://doi.org/10.1101/2025.06.09.25328726 Fadel L., Thao G., Chitre T., Rojas E., Fricko M., Domingo V., Budginas B., Guerrero L., Ghatas M., Arani N., Tabatabai N., and Pemminati S., 2025, A system-based review on effects of glucagon-like peptide-1 receptor agonists: benefits vs risks, Cureus, 17(2): e78575. https://doi.org/10.7759/cureus.78575 Gourdy P., Darmon P., Diévart F., Halimi J., and Guerci B., 2023, Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM), Cardiovascular Diabetology, 22(1): 79. https://doi.org/10.1186/s12933-023-01798-4 Hamed K., Alosaimi M., Ali B., Alghamdi A., Alkhashi T., Alkhaldi S., Altowarqi N., Alzahrani H., Alshehri A., Alkhaldi R., Alqahtani K., Alharbi N., Alhulayfi H., Sharifi S., and Dighriri I., 2024, Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes obesity and cardiovascular health through a comprehensive literature review, Cureus, 16(9): e68390. https://doi.org/10.7759/cureus.68390 Ilias I., Zabuliene L., and Rizzo M., 2025, GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks, Frontiers in Clinical Diabetes and Healthcare, 5: 1530811. https://doi.org/10.3389/fcdhc.2024.1530811 Iqbal J., Wu H., Hu N., Zhou Y., Li L., Xiao F., Wang T., Jiang H., Xu S., Huang B., and Zhou H., 2022, Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta‐analysis of randomized control trials, Obesity Reviews, 23(6): e13435. https://doi.org/10.1111/obr.13435 Jensen S., Blond M., Sandsdal R., Olsen L., Juhl C., Lundgren J., Janus C., Stallknecht B., Holst J., Madsbad S., and Torekov S., 2024, Healthy weight loss maintenance with exercise GLP-1 receptor agonist or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial, eClinicalMedicine, 69: 102475. https://doi.org/10.1016/j.eclinm.2024.102475 Kheniser K., Saxon D., and Kashyap S., 2021, Long-term weight loss strategies for obesity, The Journal of Clinical Endocrinology and Metabolism, 106(7):1854-1866. https://doi.org/10.1210/clinem/dgab091 Kojta I., Chacińska M., and Błachnio-Zabielska A., 2020, Obesity bioactive lipids and adipose tissue inflammation in insulin resistance, Nutrients, 12(5): 1305. https://doi.org/10.3390/nu12051305 Liu X., and Shu M., 2025, Application and mechanism of GLP-1 receptor agonists in the treatment of obesity complicated with type 2 diabetes mellitus, International Journal of Public Health and Medical Research, 3(3): 69-74. https://doi.org/10.62051/ijphmr.v3n3.08 Liu Y., Ruan B., Jiang H., Le S., Liu Y., Ao X., Huang Y., Shi X., Xue R., Fu X., and Wang S., 2023, The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials, The American Journal of Clinical Nutrition, 118(3): 614-626. https://doi.org/10.1016/j.ajcnut.2023.04.017 Madsbad S., and Holst J., 2025, The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines, Expert Opinion on Investigational Drugs, 34: 197-215. https://doi.org/10.1080/13543784.2025.2472408 Maple-Brown L., Shaw J., Hare M., Ng E., and Wood A., 2022, Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes, Australian Journal of General Practice, 51(7): 513-518. https://doi.org/10.31128/ajgp-07-21-6057
RkJQdWJsaXNoZXIy MjQ4ODYzNA==